“…A common feature of many autoimmune diseases is the deposition of autoantibody in tissues at various sites around the body, leading to the fixation and activation of complement, and resulting in generation of the inflammatory response 7 . Reports describe development of localized IOI in patients with RA 8,9 , the first of which describes successful treatment of a 38-year-old woman with a 6-year history of seropositive RA, with high-dose methylprednisolone 9 . However, despite use of IV methylprednisolone and MTX in our case, symptom resolution is attributed to RTX alone.…”